OncoMatch/Clinical Trials/Zanubrutinib
Zanubrutinib (BGB-3111) Clinical Trials
Zanubrutinib (Brukinsa, BGB-3111) is a next-generation, highly selective Bruton's tyrosine kinase (BTK) inhibitor designed to minimize off-target inhibition of ITK and TEC kinases, reducing the cardiac and bleeding toxicities associated with ibrutinib. It is approved for CLL/SLL, mantle cell lymphoma, Waldenström's macroglobulinemia, and other B-cell malignancies. Active trials evaluate zanubrutinib in combination with the BCL-2 inhibitor sonrotoclax (BGB-11417) — notably the CELESTIAL-RRMCL Phase 3 trial in relapsed/refractory MCL — as well as with anti-CD20 antibodies and novel agents across CLL, DLBCL, and follicular lymphoma. Eligibility typically specifies prior lines of therapy and, for combination trials, prior BTK inhibitor therapy.
Check your eligibilityRecruiting Zanubrutinib trials
Ranked by phase and US site count. Filter by your biomarker profile →
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
BeiGene
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
How OncoMatch helps you find Zanubrutinib trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every Zanubrutinib trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.